Sveriges mest populära poddar

Shire's Ornskov on $1 Billion Potential for Dry-Eye Drug(Audio)

8 min•12 juli 2016

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.

See omnystudio.com/listener for privacy information.

Fler avsnitt av Bloomberg Intelligence

Bloomberg Money: 'Gold Has Been in Bull Market for 25 Years'

15 aug.•38 min

OpenAI’s Revenue Run Rate Tops $40 Billion Ahead of IPO

14 aug.•22 min

Anthropic in Talks to Buy Startup Decart for $6 Billion

13 aug.•25 min

CoreWeave Shares Soar After Booming AI Demand Boosts Outlook

12 aug.•26 min

Apollo Inks $2.6 Billion Financing Deal With NY Yankees

11 aug.•21 min

Intel to Sell $15 Billion in Stock After AI Boosts Demand

10 aug.•22 min

Bloomberg Money: Credit Card Indicators and Golf's Changing Fanbase

8 aug.•43 min

Under Armour Cuts Sales View on Softer Demand Around the World

7 aug.•22 min

Warner Bros. Sales Fall on Loss of NBA, Weak Film Slate

6 aug.•28 min

SpaceX’s $101 Billion Unlock Heaps Pressure on Battered Shares

5 aug.•27 min

Bloomberg Intelligence med Bloomberg finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.